Bionomics Ltd ADR

About Bionomics Ltd ADR

Bionomics (NASDAQ:BNOX) focuses on developing treatments for central nervous system disorders and cancer. The company is traded on the NASDAQ under the ticker BNOX. Dedicated to science-driven innovation, Bionomics is deeply involved in the discovery and development of clinical-stage assets. Its prominent projects include BNC210, geared towards treating anxiety, PTSD, and major depressive disorder. By leveraging novel ion channel mechanisms, Bionomics aims to deliver treatments that address significant unmet medical needs. The company is committed to advancing its pipeline and creating transformative therapies that can improve the quality of life for patients worldwide.

What is Bionomics Ltd ADR known for?

Snapshot

Year founded

Employees

Adelaide, Australia

Head office

Loading Map...

Operations

All Locations

Adelaide, AU

Products and/or services of Bionomics Ltd ADR

BNC210: A lead drug candidate targeting anxiety disorders and PTSD, aiming to show efficacy in reducing anxiety symptoms with minimal side effects.
Cognition: A research program focused on developing therapies for cognitive impairment associated with aging and other neurological conditions.
Strategic Partnerships: Collaborations with pharmaceutical companies to co-develop and commercialize novel therapies, enhancing research capabilities and market reach.
ION Channel Drug Discovery: An initiative leveraging proprietary technology to discover and develop new medications targeting ion channels, crucial for neurological function.
Biomarker Discovery: Advanced biomarker identification to enhance drug discovery and personalized medicine approaches, improving treatment outcomes for patients.
Bionomics Clinical Trials: A robust pipeline of clinical trials to evaluate the safety and efficacy of pipeline drugs, supporting regulatory approval and market entry.